VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 25, 2014) - Pyng Medical Corp. (TSX VENTURE:PYT) today announced financial and operating results for the three months ended December 31, 2013. All amounts are in Canadian dollars unless stated otherwise.
The Company reported total sales of $1,536,903 for the three months ended December 31, 2013, up 47% compared with $1,043,308 for the comparative quarter last year. The sales increase was primarily due to increased U.S. military demand for the FAST1 product, which represented 83% of the sales increase. Gross margin also increased to $712,925 from $523,942 reported a year ago as a result of higher sales. Gross margin as a percentage of sales decreased from 50% to 46%, which was mainly attributed to a slight increase in production costs on some parts, as well as higher labor costs and shipping costs related to backorders and raw material shortages. Operating expenses went down 1% to $722,807 from $732,888 for the first quarter of last year as a result of lower sales and marketing expenses and product development costs.
The Company reported a reduced net loss of $82,891 for this quarter, equal to loss of $0.004 per share, compared to a net loss of $260,043 or loss of $0.02 per share one year earlier. Earnings before interest, depreciation, amortization and taxes ("EBITDA") from continuing operations were $129,244, an increase of $225,794 from negative $96,551 reported for the first quarter of fiscal 2013.
As at December 31, 2013, the Company had a cash balance of $293,543, a decrease of $22,984 compared with the balance of $316,527 as at September 30, 2013. During the quarter ended December 31, 2013, the Company closed a share for debt transaction to settle a short-term loan and issued a promissory note to settle the past due accounts payable with its major manufacturing partner. As such, the working capital position was significantly improved and the working capital deficiency decreased to $24,746 as at the quarter end from $947,852 as at September 30, 2013.
The Company continues to pursue debt and/or equity financing to help fund its working capital needs and to refinance convertible debentures maturing on August 10, 2014. There can be no assurance that these initiatives will be successful.
Full audited financial results for fiscal year ended September 30, 2013 are available on SEDAR at www.sedar.com.
About Pyng Medical Corp.
Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Pyng's expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide.
Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.
Neither the TSX Venture Exchange nor its Regulatory Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.